Market Overview

Aileron Therapeutics Announces Nonclinical Myelopreservation Results For ALRN-6924 At 2019 AACR-NCI-EORTC Conference; Results Showed It 'prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: Biotech General

 

Related Articles (ALRN)